{"id":502972,"date":"2021-06-11T07:04:07","date_gmt":"2021-06-11T11:04:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/"},"modified":"2021-06-11T07:04:07","modified_gmt":"2021-06-11T11:04:07","slug":"larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/","title":{"rendered":"Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference"},"content":{"rendered":"
\n

BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in virtual 1×1 investor meetings at the JMP Securities Life Sciences Conference taking place from June 16-17, 2021. See below for more details.<\/p>\n\n\n\n\n
Presentation Format:<\/td>\nFireside chat<\/td>\n<\/tr>\n
Date:<\/td>\nJune 16, 2021<\/td>\n<\/tr>\n
Time:<\/td>\n2:00 PM ET<\/td>\n<\/tr>\n<\/table>\n

\n About\u00a0Larimar Therapeutics<\/strong><\/p>\n

Larimar Therapeutics, Inc.\u00a0(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the\u00a0U.S.\u00a0as a potential treatment for Friedreich\u2019s ataxia (FA).\u00a0Larimar\u00a0also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit:\u00a0https:\/\/larimartx.com<\/a>.<\/p>\n

\n Investor Contact:<\/strong>
\n
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com<\/a>
(212) 915-2569<\/p>\n

\n Company Contact:<\/strong>
\n
Michael Celano
Chief Financial Officer
mcelano@larimartx.com<\/a>
(484) 414-2715<\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in virtual 1×1 investor meetings at the JMP Securities Life Sciences Conference taking place from June 16-17, 2021. See below for more details. Presentation Format: Fireside chat Date: June 16, 2021 Time: 2:00 PM ET About\u00a0Larimar Therapeutics Larimar Therapeutics, Inc.\u00a0(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the\u00a0U.S.\u00a0as a potential treatment for Friedreich\u2019s ataxia … <\/p>\n

Continue reading “Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-502972","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLarimar Therapeutics to Present at the JMP Securities Life Sciences Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in virtual 1×1 investor meetings at the JMP Securities Life Sciences Conference taking place from June 16-17, 2021. See below for more details. Presentation Format: Fireside chat Date: June 16, 2021 Time: 2:00 PM ET About\u00a0Larimar Therapeutics Larimar Therapeutics, Inc.\u00a0(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the\u00a0U.S.\u00a0as a potential treatment for Friedreich\u2019s ataxia … Continue reading "Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-11T11:04:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYxNCM0MjM3OTg4IzUwMDA3Nzg4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference\",\"datePublished\":\"2021-06-11T11:04:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/\"},\"wordCount\":186,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjYxNCM0MjM3OTg4IzUwMDA3Nzg4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/\",\"name\":\"Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjYxNCM0MjM3OTg4IzUwMDA3Nzg4OQ==\",\"datePublished\":\"2021-06-11T11:04:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjYxNCM0MjM3OTg4IzUwMDA3Nzg4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjYxNCM0MjM3OTg4IzUwMDA3Nzg4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/","og_locale":"en_US","og_type":"article","og_title":"Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference - Market Newsdesk","og_description":"BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in virtual 1×1 investor meetings at the JMP Securities Life Sciences Conference taking place from June 16-17, 2021. See below for more details. Presentation Format: Fireside chat Date: June 16, 2021 Time: 2:00 PM ET About\u00a0Larimar Therapeutics Larimar Therapeutics, Inc.\u00a0(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the\u00a0U.S.\u00a0as a potential treatment for Friedreich\u2019s ataxia … Continue reading \"Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-11T11:04:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYxNCM0MjM3OTg4IzUwMDA3Nzg4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference","datePublished":"2021-06-11T11:04:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/"},"wordCount":186,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYxNCM0MjM3OTg4IzUwMDA3Nzg4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/","name":"Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYxNCM0MjM3OTg4IzUwMDA3Nzg4OQ==","datePublished":"2021-06-11T11:04:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYxNCM0MjM3OTg4IzUwMDA3Nzg4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYxNCM0MjM3OTg4IzUwMDA3Nzg4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/502972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=502972"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/502972\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=502972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=502972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=502972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}